NasdaqGS:RGENLife Sciences
Repligen (RGEN) Stock Valuation After RBC Coverage Resumes And Q1 2026 Beat
RBC coverage and Q1 earnings put Repligen (RGEN) back in focus
RBC Capital’s decision to resume coverage of Repligen (RGEN) with a favorable view, following Q1 2026 results that topped revenue and adjusted EPS forecasts, has put the stock back on many investors’ watchlists.
See our latest analysis for Repligen.
Repligen’s share price has climbed 26.95% over the past 30 days and 13.45% over 90 days, yet remains down 20.54% year to date, while the 1 year total shareholder return is 2.41%,...